Powered by

ContraVir Expands Scientific Advisory Board to Focus on Seeking Curative Therapy for Hepatitis B

Jul 18, 2016 - PR Newswire
Board and Executive Moves

ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today the expansion of its Scientific Advisory Board (SAB) with internationally recognized hepatitis B (HBV) experts that add significant scientific, clinical and industry expertise.� Current SAB member Carol L. Brosgart, M.D., has been appointed Chair of the SAB in support of ContraVir's development of a potentially curative th...